Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

Am J Kidney Dis. 2006 Sep;48(3):e27-9. doi: 10.1053/j.ajkd.2006.05.018.

Abstract

A 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma. Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors, our patient was administered rapamycin for 6 months. During this time, the renal angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in size again after readministration of rapamycin.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiomyolipoma / drug therapy*
  • Angiomyolipoma / etiology
  • Antibiotics, Antineoplastic / therapeutic use*
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / etiology
  • Male
  • Sirolimus / therapeutic use*
  • Treatment Outcome
  • Tuberous Sclerosis / complications*

Substances

  • Antibiotics, Antineoplastic
  • Sirolimus